Walicka Magdalena, Jozwiak Jacek, Rzeszotarski Jacek, Zonenberg Anna, Masierek Malgorzata, Bijos Pawel, Franek Edward
Department of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital of the Ministry of the Inferior and Administration, Warsaw, Poland.
Department of Public Health, Czestochowa University of Technology, Czestochowa, Poland.
Diabetes Ther. 2019 Apr;10(2):587-596. doi: 10.1007/s13300-019-0570-1. Epub 2019 Feb 8.
Studies assessing the relationship between glycated haemoglobin (HbA1c) and average blood glucose (ABG) were conducted in small groups of patients on different treatments and may be biased for these reasons. The aim of the study was to assess the relationship between HbA1c and ABG in a large group of type 2 diabetes patients treated with premix insulin.
In 4257 patients treated with premixed insulin, the parallel point-of-care assessment of HbA1c and ABG from the preceding 90 days (ABG90), calculated automatically from all values measured by the glucometer, was performed twice. The regression formulas and respective values of HbA1c and ABG90 were calculated.
The mean number of recorded glucose values/patient was 2.37 estimations per day. The regression formula calculated using data from the first assessment was HbA1c = 5.28 + 0.01487 × ABG90 and that using data from the second one was HbA1c = 4.78 + 0.01683 × ABG90. The slopes of the regression lines are lower than that in a similar analysis from the A1c-Derived Average Glucose (ADAG) study. The comparison of ADAG formula and the formula derived from the present study shows that both formulas give similar results at low HbA1c values, but differ at higher HbA1c values. Additionally, the 95% confidence interval is broader in the PROGENS study e.g. a 95% probability of certainty that the actual HbA1c value was greater than 7.0% (53 mmol/mol) was achieved only at an ABG90 value of 220 mg/dL.
The relationship between HbA1c and ABG estimations may be different in various patients; therefore, it seems that the use of one equation in all populations may not be reliable. Broad assessment of ABG as a tool that may replace HbA1c measurements should be recommended only with caution, providing the possible limitations and confidence intervals.
Bioton S.A.
评估糖化血红蛋白(HbA1c)与平均血糖(ABG)之间关系的研究是在接受不同治疗的小部分患者中进行的,可能因此存在偏差。本研究的目的是评估接受预混胰岛素治疗的一大群2型糖尿病患者中HbA1c与ABG之间的关系。
在4257例接受预混胰岛素治疗的患者中,对糖化血红蛋白和前90天的平均血糖(ABG90)进行了两次即时平行评估,ABG90由血糖仪测量的所有值自动计算得出。计算了HbA1c和ABG90的回归公式及各自的值。
每位患者记录的血糖值平均数量为每天2.37次测定。使用首次评估数据计算的回归公式为HbA1c = 5.28 + 0.01487×ABG90,使用第二次评估数据计算的回归公式为HbA1c = 4.78 + 0.01683×ABG90。回归线的斜率低于糖化血红蛋白衍生平均血糖(ADAG)研究中类似分析的斜率。ADAG公式与本研究得出的公式比较表明,两个公式在低HbA1c值时给出相似结果,但在高HbA1c值时有所不同。此外,在PROGENS研究中95%置信区间更宽,例如只有当ABG90值为220 mg/dL时,实际HbA1c值大于7.0%(53 mmol/mol)才有95%的确定概率。
HbA1c与ABG评估之间的关系在不同患者中可能不同;因此,在所有人群中使用一个公式似乎不可靠。仅在谨慎提供可能的局限性和置信区间的情况下,才应推荐将ABG作为可能替代HbA1c测量的工具进行广泛评估。
Bioton S.A.